ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

72.18 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

1 Mooning Stock for Long-Term Investors and 2 That Underwhelm

August 22, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Via StockStory

Topics Emissions

Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment

August 19, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Healthcare Stocks We’re Skeptical Of

August 18, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six...

Via StockStory

Topics Stocks

ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors ↗

August 08, 2025

Via Stocktwits

Topics Government

Earnings Preview For ANI Pharmaceuticals ↗

August 07, 2025

Via Benzinga

Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Earnings Economy

ANIP Q2 Deep Dive: Rare Disease Expansion Fuels Outperformance, Generics Maintain Solid Trajectory

August 11, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 53.1% year on year to $211.4 million. The...

Via StockStory

Why ANI Pharmaceuticals (ANIP) Stock Is Up Today

August 08, 2025

Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 18.4% in the morning session after the company reported second-quarter earnings and revenue that surpassed analyst...

Via StockStory

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 08, 2025

Via Benzinga

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Reports Record Q2 2025 Earnings, Beats Estimates and Raises Full-Year Guidance ↗

August 08, 2025

ANI Pharmaceuticals reports record Q2 2025 earnings, beating estimates with $211.4M revenue and $1.80 EPS. Shares surge 6.5% as company raises full-year guidance.

Via Chartmill

Topics Earnings

ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2: Strong Sales, Stock Soars

August 08, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q2 CY2025, with sales up 53.1% year on year to $211.4 million. The company’s full-year...

Via StockStory

Earnings Scheduled For August 8, 2025 ↗

August 08, 2025

Via Benzinga

ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect

August 06, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before the bell. Here’s what to look for.

Via StockStory

Topics Government World Trade

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

July 29, 2025

From CG Oncology Inc.

Via GlobeNewswire

Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

July 28, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks

July 16, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Value Stocks Skating on Thin Ice

July 15, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

3 Growth Stocks in Hot Water

July 08, 2025

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s...

Via StockStory

ANI Pharmaceuticals (NASDAQ:ANIP) Q1 Earnings: Leading The Generic Pharmaceuticals Pack

June 19, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

June 16, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

3 Healthcare Stocks with Mounting Challenges

June 12, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...

Via StockStory

Topics Stocks

3 Cash-Producing Stocks in the Doghouse

June 06, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

ANIP Q1 CY2025 Earnings Call: Generics, Rare Disease Drive Growth; Retina Headwinds Noted

June 04, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) exceeded Wall Street’s revenue expectations in Q1 CY2025, as sales rose 43.4% year on year to $197.1 million. Its non-GAAP EPS of...

Via StockStory

Topics World Trade

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter ↗

May 27, 2025

Via Benzinga

1 Russell 2000 Stock with Solid Fundamentals and 2 to Steer Clear Of

May 23, 2025

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers

May 22, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Value Stocks with Mounting Challenges

May 22, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

3 Small-Cap Stocks Walking a Fine Line

May 13, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

ANI Pharma Reports Upbeat Q1 Earnings, Revises Full-Year Outlook: Retail’s Pleased ↗

May 09, 2025

The CEO dismissed the impact of Trump tariffs, noting that the company produces a major portion of its goods in the U.S.

Via Stocktwits

Topics Government World Trade

Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact ↗

May 09, 2025

ANI Pharmaceuticals Q1 revenue rose 43.4% to $197.12 million, EPS beat consensus, and 2025 guidance was raised on strong Cortrophin Gel and generics growth.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.